Biovail Sues Andrx Over Planned Cardizem Generic

Law360, New York (August 16, 2005, 12:00 AM EDT) -- A popular drug for controlling blood pressure is at the center of a new patent lawsuit brought by Biovail Laboratories against generics maker Andrx Pharmaceuticals.

Biovail, based in Barbados, sued Florida-based Andrx in Delaware district court. It asserted a patent that reshaped the hypertension drug niche in the mid-1990s.

Andrx completed an Abbreviated New Drug Application with the Food and Drug Administration, stating its intentions to create and market a generic version of Biovail’s Cardizem LA. Compelled by the Hatch-Waxman Act, Andrx informed Biovail of its...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.